Precision cancer therapy: profiting from tumor specific defects in the DNA damage tolerance system
DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first li...
Saved in:
Published in | Oncotarget Vol. 9; no. 27; pp. 18832 - 18843 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Impact Journals LLC
10.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/18). A survey of The Cancer Genome Atlas (TCGA) revealed a high frequency of tumors presents RAD6/RAD18 bi-allelic inactivating deletions. For instance, 11% of renal cell carcinoma and 5% of pancreatic tumors have inactivating
-deletions and 7% of malignant peripheral nerve sheath tumors lack
. To determine the potential benefit for tumor-specific DDT defects, we followed a genetic approach by establishing unique sets of DDT-proficient
and -defective
lymphoma and breast cancer cell lines. In the absence of exogenous DNA damage,
tumors grew comparably to their
controls
and
. However, DDT-defective lymphomas and breast cancers were compared to their DDT-proficient controls hypersensitive to the chemotherapeutic drug cisplatin (CsPt), both
and
CsPt strongly inhibited tumor growth and the overall survival of tumor bearing mice greatly improved in the DDT-defective condition. These insights open new therapeutic possibilities for precision cancer medicine with DNA damaging chemotherapeutics and optimize Next-Generation-Sequencing (NGS)-based cancer-diagnostics, -therapeutics, and -prognosis. |
---|---|
AbstractList | DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/18). A survey of The Cancer Genome Atlas (TCGA) revealed a high frequency of tumors presents RAD6/RAD18 bi-allelic inactivating deletions. For instance, 11% of renal cell carcinoma and 5% of pancreatic tumors have inactivating
-deletions and 7% of malignant peripheral nerve sheath tumors lack
. To determine the potential benefit for tumor-specific DDT defects, we followed a genetic approach by establishing unique sets of DDT-proficient
and -defective
lymphoma and breast cancer cell lines. In the absence of exogenous DNA damage,
tumors grew comparably to their
controls
and
. However, DDT-defective lymphomas and breast cancers were compared to their DDT-proficient controls hypersensitive to the chemotherapeutic drug cisplatin (CsPt), both
and
CsPt strongly inhibited tumor growth and the overall survival of tumor bearing mice greatly improved in the DDT-defective condition. These insights open new therapeutic possibilities for precision cancer medicine with DNA damaging chemotherapeutics and optimize Next-Generation-Sequencing (NGS)-based cancer-diagnostics, -therapeutics, and -prognosis. DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/18). A survey of The Cancer Genome Atlas (TCGA) revealed a high frequency of tumors presents RAD6/RAD18 bi-allelic inactivating deletions. For instance, 11% of renal cell carcinoma and 5% of pancreatic tumors have inactivating RAD18-deletions and 7% of malignant peripheral nerve sheath tumors lack RAD6B. To determine the potential benefit for tumor-specific DDT defects, we followed a genetic approach by establishing unique sets of DDT-proficient PcnaK164 and -defective PcnaK164R lymphoma and breast cancer cell lines. In the absence of exogenous DNA damage, PcnaK164R tumors grew comparably to their PcnaK164 controls in vitro and in vivo. However, DDT-defective lymphomas and breast cancers were compared to their DDT-proficient controls hypersensitive to the chemotherapeutic drug cisplatin (CsPt), both in vitro and in vivo. CsPt strongly inhibited tumor growth and the overall survival of tumor bearing mice greatly improved in the DDT-defective condition. These insights open new therapeutic possibilities for precision cancer medicine with DNA damaging chemotherapeutics and optimize Next-Generation-Sequencing (NGS)-based cancer-diagnostics, -therapeutics, and -prognosis. DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/18). A survey of The Cancer Genome Atlas (TCGA) revealed a high frequency of tumors presents RAD6/RAD18 bi-allelic inactivating deletions. For instance, 11% of renal cell carcinoma and 5% of pancreatic tumors have inactivating RAD18 -deletions and 7% of malignant peripheral nerve sheath tumors lack RAD6B . To determine the potential benefit for tumor-specific DDT defects, we followed a genetic approach by establishing unique sets of DDT-proficient Pcna K164 and -defective Pcna K164R lymphoma and breast cancer cell lines. In the absence of exogenous DNA damage, Pcna K164R tumors grew comparably to their Pcna K164 controls in vitro and in vivo . However, DDT-defective lymphomas and breast cancers were compared to their DDT-proficient controls hypersensitive to the chemotherapeutic drug cisplatin (CsPt), both in vitro and in vivo. CsPt strongly inhibited tumor growth and the overall survival of tumor bearing mice greatly improved in the DDT-defective condition. These insights open new therapeutic possibilities for precision cancer medicine with DNA damaging chemotherapeutics and optimize Next-Generation-Sequencing (NGS)-based cancer-diagnostics, -therapeutics, and -prognosis. |
Author | van der Wiel, Rianne Buoninfante, Olimpia Alessandra van den Berk, Paul C M Jacobs, Heinz Zavrakidis, Ioannis Pilzecker, Bas Aslam, Muhammad Assad van de Ven, Marieke |
Author_xml | – sequence: 1 givenname: Olimpia Alessandra surname: Buoninfante fullname: Buoninfante, Olimpia Alessandra organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands – sequence: 2 givenname: Bas surname: Pilzecker fullname: Pilzecker, Bas organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands – sequence: 3 givenname: Muhammad Assad surname: Aslam fullname: Aslam, Muhammad Assad organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands – sequence: 4 givenname: Ioannis surname: Zavrakidis fullname: Zavrakidis, Ioannis organization: Division of Psychosocial Research and Epidemiology, Amsterdam, CX 1066, The Netherlands – sequence: 5 givenname: Rianne surname: van der Wiel fullname: van der Wiel, Rianne organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands – sequence: 6 givenname: Marieke surname: van de Ven fullname: van de Ven, Marieke organization: Mouse Clinic for Cancer and Aging research (MCCA) Transgenic Facility, The Netherlands Cancer Institute, Amsterdam, CX 1066, The Netherlands – sequence: 7 givenname: Paul C M surname: van den Berk fullname: van den Berk, Paul C M organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands – sequence: 8 givenname: Heinz surname: Jacobs fullname: Jacobs, Heinz organization: Division of Tumor Biology and Immunology, Amsterdam, CX 1066, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29721165$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkctOBCEQRYnR-P4AN4alm1GgYXpwYWLGZzJRF7omNBQjphtaYEzm7211fNWmKuHeU6TuDloPMQBCB5Qc08m4YicxmFh0mkM5Zryu6zW0TSWXIyZEtf5n3kL7Ob-QoQSvJ0xuoi0ma0bpWGyj5iGB8dnHgI0OBhIuz5B0vzzFfYrOFx_m2KXY4bLoYsK5H-TOG2zBgSkZ-_DhwBd359jqTs8Bl9gOhIGF8zIX6PbQhtNthv1V30VPV5eP05vR7P76dno-GxlW0zJy0hBHtOBSNxy05aYaC0u4NdZoPSGNNLWQ1knWjIEz0Nwy7givGuYkHy6yi86-uP2i6cAaCCXpVvXJdzotVdRe_X8J_lnN45sSkrFKyAFwtAKk-LqAXFTns4G21QHiIitGKs4kndTVIKVfUpNizgnczxpK1Gc86jce9RnP4Dn8-78fx3cY1Ttl3pMz |
CitedBy_id | crossref_primary_10_1371_journal_pone_0210526 crossref_primary_10_1093_nar_gkz531 crossref_primary_10_1093_nar_gkac545 crossref_primary_10_3390_genes10010010 crossref_primary_10_1093_pnasnexus_pgae242 crossref_primary_10_3389_fonc_2020_00670 crossref_primary_10_1080_14728222_2021_1864321 crossref_primary_10_1002_cam4_2203 crossref_primary_10_3389_fonc_2021_822500 crossref_primary_10_3389_fphar_2021_596535 crossref_primary_10_1038_s41598_020_65767_7 crossref_primary_10_1080_10409238_2019_1651817 |
Cites_doi | 10.1038/nature00991 10.1128/MCB.24.10.4267-4274.2004 10.1016/j.cell.2007.05.003 10.4161/cc.3.1.623 10.1084/jem.20070902 10.1038/nature03445 10.1038/cr.2008.4 10.1073/pnas.0702955104 10.1038/nature08467 10.1093/nar/gkw123 10.1158/2159-8290.CD-12-0095 10.1126/science.1120615 10.1038/nature01965 10.1038/nrm1781 10.1126/scisignal.2004088 10.1016/j.molcel.2017.08.010 10.1093/nar/gni187 10.1038/ng.3905 10.1073/pnas.1706508114 10.1128/MCB.01478-07 10.1038/356215a0 10.1128/MMBR.00034-08 10.1016/S1097-2765(04)00259-X 10.1146/annurev.biochem.74.082803.133250 10.1038/nrc3088 10.1093/emboj/19.13.3388 10.1016/j.ejphar.2014.07.025 10.1073/pnas.95.10.5678 |
ContentType | Journal Article |
Copyright | Copyright: © 2018 Buoninfante et al. 2018 |
Copyright_xml | – notice: Copyright: © 2018 Buoninfante et al. 2018 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.18632/oncotarget.24777 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1949-2553 |
EndPage | 18843 |
ExternalDocumentID | 10_18632_oncotarget_24777 29721165 |
Genre | Journal Article |
GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK FRJ GX1 HYE KQ8 M48 M~E NPM OK1 PGMZT RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c271t-f9c0f0a549ab4ead4c365d04dcdcaa80b9c759df92b6e42ea4d24f043b2f94863 |
IEDL.DBID | RPM |
ISSN | 1949-2553 |
IngestDate | Tue Sep 17 21:22:07 EDT 2024 Fri Aug 16 11:20:21 EDT 2024 Fri Aug 23 01:32:07 EDT 2024 Wed Oct 16 00:58:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 27 |
Keywords | precision cancer medicine DNA damage tolerance cancer target cisplatin chemotherapy |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c271t-f9c0f0a549ab4ead4c365d04dcdcaa80b9c759df92b6e42ea4d24f043b2f94863 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922359/ |
PMID | 29721165 |
PQID | 2034291873 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5922359 proquest_miscellaneous_2034291873 crossref_primary_10_18632_oncotarget_24777 pubmed_primary_29721165 |
PublicationCentury | 2000 |
PublicationDate | 2018-Apr-10 2018-04-10 20180410 |
PublicationDateYYYYMMDD | 2018-04-10 |
PublicationDate_xml | – month: 04 year: 2018 text: 2018-Apr-10 day: 10 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Oncotarget |
PublicationTitleAlternate | Oncotarget |
PublicationYear | 2018 |
Publisher | Impact Journals LLC |
Publisher_xml | – name: Impact Journals LLC |
References | Ulrich (11) 2004; 3 Jentsch (7) 2002; 419 Walker (13) 2009; 73 Bartek (2) 2009; 461 Prakash (8) 2004; 24 Bradley (28) 1992; 356 Prakash (19) 2007; 27 Xiao (25) 1998; 95 Lehmann (9) 2004; 14 Jentsch (26) 2000; 19 Jacobs (21) 2007; 204 Jacobs (27) 2005; 33 Friedberg (3) 2005; 6 Jentsch (4) 2007; 129 Kunkel (12) 2008; 18 Wesseling (24) 2017; 49 Tchounwou (23) 2014; 740 Jacobs (16) 2016; 44 Goldberg (18) 2012; 2 Borst (22) 2007; 104 Ulrich (5) 2003; 425 Prakash (14) 2005; 74 West (15) 2011; 11 Jacobs (20) 2017; 114 Smith (1) 2005; 434 Schultz (17) 2013; 6 Dikic (10) 2005; 310 Cortez (6) 2017; 67 |
References_xml | – volume: 419 start-page: 135 year: 2002 ident: 7 article-title: RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO publication-title: Nature doi: 10.1038/nature00991 contributor: fullname: Jentsch – volume: 24 start-page: 4267 year: 2004 ident: 8 article-title: Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in Saccharomyces cerevisiae publication-title: Mol Cell Biol doi: 10.1128/MCB.24.10.4267-4274.2004 contributor: fullname: Prakash – volume: 129 start-page: 665 year: 2007 ident: 4 article-title: PCNA, the maestro of the replication fork publication-title: Cell doi: 10.1016/j.cell.2007.05.003 contributor: fullname: Jentsch – volume: 3 start-page: 15 year: 2004 ident: 11 article-title: How to activate a damage-tolerant polymerase: consequences of PCNA modifications by ubiquitin and SUMO publication-title: Cell Cycle doi: 10.4161/cc.3.1.623 contributor: fullname: Ulrich – volume: 204 start-page: 1989 year: 2007 ident: 21 article-title: A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification publication-title: J Exp Med doi: 10.1084/jem.20070902 contributor: fullname: Jacobs – volume: 434 start-page: 917 year: 2005 ident: 1 article-title: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy publication-title: Nature doi: 10.1038/nature03445 contributor: fullname: Smith – volume: 18 start-page: 148 year: 2008 ident: 12 article-title: The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases publication-title: Cell Res doi: 10.1038/cr.2008.4 contributor: fullname: Kunkel – volume: 104 start-page: 12117 year: 2007 ident: 22 article-title: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0702955104 contributor: fullname: Borst – volume: 461 start-page: 1071 year: 2009 ident: 2 article-title: The DNA-damage response in human biology and disease publication-title: Nature doi: 10.1038/nature08467 contributor: fullname: Bartek – volume: 44 start-page: 4734 year: 2016 ident: 16 article-title: PrimPol prevents APOBEC/AID family mediated DNA mutagenesis publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw123 contributor: fullname: Jacobs – volume: 2 start-page: 401 year: 2012 ident: 18 article-title: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0095 contributor: fullname: Goldberg – volume: 310 start-page: 1821 year: 2005 ident: 10 article-title: Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis publication-title: Science doi: 10.1126/science.1120615 contributor: fullname: Dikic – volume: 425 start-page: 188 year: 2003 ident: 5 article-title: Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation publication-title: Nature doi: 10.1038/nature01965 contributor: fullname: Ulrich – volume: 6 start-page: 943 year: 2005 ident: 3 article-title: Suffering in silence: the tolerance of DNA damage publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm1781 contributor: fullname: Friedberg – volume: 6 start-page: l1 year: 2013 ident: 17 article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal publication-title: Sci Signal doi: 10.1126/scisignal.2004088 contributor: fullname: Schultz – volume: 67 start-page: 882 year: 2017 ident: 6 article-title: Replication Fork Slowing and Reversal upon DNA Damage Require PCNA Polyubiquitination and ZRANB3 DNA Translocase Activity publication-title: Mol Cell doi: 10.1016/j.molcel.2017.08.010 contributor: fullname: Cortez – volume: 33 start-page: e188 year: 2005 ident: 27 article-title: Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA publication-title: Nucleic Acids Res doi: 10.1093/nar/gni187 contributor: fullname: Jacobs – volume: 49 start-page: 1219 year: 2017 ident: 24 article-title: Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma publication-title: Nat Genet doi: 10.1038/ng.3905 contributor: fullname: Wesseling – volume: 114 start-page: E6875 year: 2017 ident: 20 article-title: DNA damage tolerance in hematopoietic stem and progenitor cells in mice publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1706508114 contributor: fullname: Jacobs – volume: 27 start-page: 8401 year: 2007 ident: 19 article-title: Complex formation of yeast Rev1 with DNA polymerase eta publication-title: Mol Cell Biol doi: 10.1128/MCB.01478-07 contributor: fullname: Prakash – volume: 356 start-page: 215 year: 1992 ident: 28 article-title: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours publication-title: Nature doi: 10.1038/356215a0 contributor: fullname: Bradley – volume: 73 start-page: 134 year: 2009 ident: 13 article-title: Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance publication-title: Microbiol Mol Biol Rev doi: 10.1128/MMBR.00034-08 contributor: fullname: Walker – volume: 14 start-page: 491 year: 2004 ident: 9 article-title: Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage publication-title: Mol Cell doi: 10.1016/S1097-2765(04)00259-X contributor: fullname: Lehmann – volume: 74 start-page: 317 year: 2005 ident: 14 article-title: Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.74.082803.133250 contributor: fullname: Prakash – volume: 11 start-page: 467 year: 2011 ident: 15 article-title: DNA interstrand crosslink repair and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc3088 contributor: fullname: West – volume: 19 start-page: 3388 year: 2000 ident: 26 article-title: Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair publication-title: EMBO J doi: 10.1093/emboj/19.13.3388 contributor: fullname: Jentsch – volume: 740 start-page: 364 year: 2014 ident: 23 article-title: Cisplatin in cancer therapy: molecular mechanisms of action publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2014.07.025 contributor: fullname: Tchounwou – volume: 95 start-page: 5678 year: 1998 ident: 25 article-title: MMS2, encoding a ubiquitin-conjugating-enzyme-like protein, is a member of the yeast error-free postreplication repair pathway publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.95.10.5678 contributor: fullname: Xiao |
SSID | ssj0000547829 |
Score | 2.2962234 |
Snippet | DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 18832 |
SubjectTerms | Research Paper |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF5qvXgRxVd9sYInITXdTJKuICI-EKHiwYK3sE8s2ERjCvrv3dmk1aoXz8ku4dvZ3W8yM98QcqgjHVrFIIhA-l83MhBMisCC5jIURgpflTa4S26GcPsYP7bItL1VA-Dbn64d9pMals_d99ePM7fhT3HD95OIHReoY-ATp7sM0jRdIIsMIkCDHzRsv5b6Bncfch9nBh44Mh01cc4_Z5m_qX7Rz59ZlN-upesVstzwSXpeG8AqaZl8jcj7smmdQxWuaknrMquPE-p7dGOqM8XCElpNxkVJsdwSU4aoNj67g45yHEEv786pFmN35NCqeDbYg8PQWvt5nQyvrx4uboKmmUKgWNqrAstVaEPh3EEhwZkPqCiJdQhaaSVEP5RcpTHXljOZGGBGgGZgQ4gksxwcQBuknRe52SLUeSCOhtkYhBbgZhHKGQJYzdwImYikQ46mwGUvtWZGhr4Gopx9oZx5lDvkYApt5iwbwxUiN8XkLWOoTsh7_TTqkM0a6tl0DEWHekncIencIsxeQNXs-Sf56MmrZ8fcMaKYb__nI3fIkiNKfYwi9cJd0q7KidlzZKSS-97EPgGqRuSE priority: 102 providerName: Scholars Portal |
Title | Precision cancer therapy: profiting from tumor specific defects in the DNA damage tolerance system |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29721165 https://search.proquest.com/docview/2034291873 https://pubmed.ncbi.nlm.nih.gov/PMC5922359 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEB2RnHqpQKVtgEaL1FMlJ_Z6_LG9ISggpCAORcrN2k81ErFRcA78e3bWNg3l1osv9q6sNyPPjPfNG4DvJjWx0xyjFFX4daMiyZWMHBqhYmmVDF1pi9v8-h5vltlyD7KhFyaQ9rVazeqH9axe_Qncyse1ng88sfnd4jwTPqhlYj6CUZGmOyV6J-iNPuqJ_gSzzFM-b0jnIBCrZxyLggbvcVKtSSik7Iajdznmv1TJndhzuQ8f-6SRnXUvdwB7tv4E6m7Tz8dhmky3YV0v1fNPFgZxE5-ZUfcIa7frZsOop5J4QczYQOFgq5pWsIvbM2bk2n9XWNs8WBq0YVkn8HwI95e_fp9fR_3EhEjzImkjJ3TsYulrPqnQ-wjqNM9MjEYbLWUZK6GLTBgnuMotcivRcHQxpoo7gR6rzzCum9p-BebLDJ9ruQylkeh3kdpbG53hfoXKZT6BHwNw1WMnjFFRQUGAV38BrwLgEzgdoK28-9KZhKxts32qOEkQiqQs0gl86aB-3W6w0QSKN0Z4fYCksd_e8R4TJLJ7Dzn675XH8MGnRiWdGyXxCYzbzdZ-8-lHq6Ywulom_rrAchpc7wVzSeMe |
link.rule.ids | 230,315,733,786,790,891,2236,24346,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RemgvfagPlrbUlTghJZt1Jsm6N0SLFsquOEDFLfJTrGATtM0e6K-vx0noQk_07NhK9I09M_E33wDsmtQkTnOMUlTh142KJFcycmiESqRVMlSlTWf55ByPL7KLDcj6WphA2tdqHlfXi7iaXwZu5c1CD3ue2PB0epAJ79QyMXwCT_1-5dlakt5KeqP3e6K7wxznKR_WpHQQqNUxx6Kg1nucdGtG5FTWHdI_UeZDsuSa9zl8CT_7925JJ1fxqlGx_v1A0vHRH_YKXnTxKNtvh1_Dhq3egDpddq13mCarWLK2TOv2Kws9vokqzagwhTWrRb1kVK5JlCNmbGCHsHlFM9i32T4zcuGPLNbU15Z6eFjWake_hfPD72cHk6hrxhBpXoyayAmduET6dFIq9OaHOs0zk6DRRks5TpTQRSaME1zlFrmVaDi6BFPFnUAPwjvYrOrKbgHzGYwP41yG0kj0q0jtDQmd4X6GymU-gL0ekfKm1dwoKVchJMu_SJYByQF86TEr_c6g6w5Z2Xr1q-SkbihG4yIdwPsWw7vlevAHUNxD9-4BUt2-P-IxC-rbHUbb_z3zMzybnE1PypOj2Y8P8NxHYGO6nholH2GzWa7sJx_lNGon2PQfNMADWw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkRAXHuK1bQEjcULKY51Jsu6talmVR1d7oFLFJfJTXdFNVkv20P56PE5StuXWc2wr0Tf2zMTffAPwyWQmdZpjlKEKv25UJLmSkUMjVCqtkqEq7XRWnJzht_P8fKvVVyDta7WI68tlXC8uArdytdTJwBNL5qdHufBOLRfJyrjkITzye5aXW4l6J-uN3veJ_h5zUmQ8aUjtINCrY45lSe33OGnXjMmxbDul_yLNu4TJLQ80fQa_hnfviCe_402rYn19R9bxXh_3HJ72cSk77Ia8gAe2fglqvu5b8DBN1rFmXbnW1QELvb6JMs2oQIW1m2WzZlS2SdQjZmxgibBFTTPY8eyQGbn0Rxdrm0tLvTws6zSkX8HZ9MvPo5Oob8oQaV6O28gJnbpU-rRSKvRmiDorcpOi0UZLOUmV0GUujBNcFRa5lWg4uhQzxZ1AD8Rr2Kmb2r4F5jMZH865HKWR6FeR2hsUOsP9DFXIYgSfB1SqVae9UVHOQmhW_9CsApoj-DjgVvkdQtcesrbN5k_FSeVQjCdlNoI3HY43yw0GMILyFsI3A0h9-_YTj1tQ4e5x2r33zA_weH48rX58nX3fgyc-EJvQLdU43Yeddr2x73yw06r3waz_AjFPBds |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Precision+cancer+therapy%3A+profiting+from+tumor+specific+defects+in+the+DNA+damage+tolerance+system&rft.jtitle=Oncotarget&rft.au=Buoninfante%2C+Olimpia+Alessandra&rft.au=Pilzecker%2C+Bas&rft.au=Aslam%2C+Muhammad+Assad&rft.au=Zavrakidis%2C+Ioannis&rft.date=2018-04-10&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=9&rft.issue=27&rft.spage=18832&rft.epage=18843&rft_id=info:doi/10.18632%2Foncotarget.24777&rft.externalDBID=n%2Fa&rft.externalDocID=10_18632_oncotarget_24777 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |